Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 22449197)

1.

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD, Lister TA, Gribben JG.

Br J Haematol. 2012 Jun;157(5):580-5. doi: 10.1111/j.1365-2141.2012.09106.x. Epub 2012 Mar 26.

PMID:
22449197
2.

Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.

Wondergem MJ, Dijkstra FS, Visser OJ, Zweegman S, Ossenkoppele GJ, Witte BI, Janssen JJ.

Bone Marrow Transplant. 2014 Apr;49(4):513-8. doi: 10.1038/bmt.2013.221. Epub 2014 Jan 13.

PMID:
24419517
3.

Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.

Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringdén O; Nordic Group for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2014 Jan;20(1):135-8. doi: 10.1016/j.bbmt.2013.10.014. Epub 2013 Oct 17.

4.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28.

5.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

6.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

7.

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22. doi: 10.1016/j.bbmt.2012.08.014. Epub 2012 Aug 29.

PMID:
22940057
8.

Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.

El-Cheikh J, Vazquez A, Crocchiolo R, Furst S, Calmels B, Castagna L, Lemarie C, Granata A, Ladaique P, Oudin C, Faucher C, Chabannon C, Blaise D.

Am J Hematol. 2012 Dec;87(12):1074-8. doi: 10.1002/ajh.23319. Epub 2012 Aug 22.

PMID:
22911907
9.

Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.

Bilmon IA, Kwan J, Gottlieb D, Kerridge I, McGurgan M, Huang G, George B, Hertzberg M, Bradstock KF.

Intern Med J. 2013 Feb;43(2):191-6. doi: 10.1111/j.1445-5994.2012.02843.x.

PMID:
22646924
10.

Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

Shin HC, Lee YJ, Moon JH, Lee SJ, Kang BW, Chae YS, Kim JG, Choi JY, Seo JW, Kim YK, Suh JS, Sohn SK.

Korean J Intern Med. 2012 Mar;27(1):72-83. doi: 10.3904/kjim.2012.27.1.72. Epub 2012 Feb 28.

11.

Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.

Mineishi S.

JAMA. 2011 Nov 2;306(17):1918-20. doi: 10.1001/jama.2011.1612. No abstract available.

PMID:
22045771
12.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

13.

Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.

Ikegame K, Yoshihara S, Taniguchi Y, Kaida K, Inoue T, Okada M, Taniguchi K, Hasei H, Tamaki H, Fujioka T, Kato R, Soma T, Ogawa H.

Exp Hematol. 2011 Aug;39(8):880-90. doi: 10.1016/j.exphem.2011.05.007. Epub 2011 May 27.

PMID:
21689724
14.

Allogeneic stem cell transplantation in follicular lymphoma.

Khouri IF.

Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Review.

15.

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen M.

Blood. 2011 Jun 23;117(25):6963-70. doi: 10.1182/blood-2011-01-332007. Epub 2011 Apr 4.

16.

Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.

Hong JY, Choi MK, Kim DH, Kim SJ, Kim K, Kim WS, Chung CW, Kim HO, Min YH, Jang JH.

Transplant Proc. 2010 Nov;42(9):3723-8. doi: 10.1016/j.transproceed.2010.09.005.

PMID:
21094846
17.

Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.

Tajika K, Yamaguchi H, Mizuki T, Nakamura H, Nakayama K, Dan K.

J Nippon Med Sch. 2010 Oct;77(5):254-9.

18.

Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.

Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K, Patel M, Rasheed W, Saleh AJ, Bakr M, Ahmed S, Ibrahim K, Hussain F, Elkum N, Elhassan T, Nurgat Z, Chaudhri N, Aljurf M.

Biol Blood Marrow Transplant. 2011 May;17(5):717-22. doi: 10.1016/j.bbmt.2010.08.013. Epub 2010 Aug 22.

19.

Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.

Patil S, Spencer A, Schwarer A, Lewis I, Hertzberg M, Avery S, Wei A, Noutsos T, Paul E, Taouk Y, Muirhead J.

Bone Marrow Transplant. 2010 Jul;45(7):1154-60. doi: 10.1038/bmt.2009.322. Epub 2009 Nov 9.

PMID:
19898502
20.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.

Blood. 2009 Jul 30;114(5):1099-109. doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk